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BACKGROUND AND PURPOSE
Allergic conjunctivitis is an eye inflammation that involves the infiltration of immune cells into the conjunctiva via cell surface-
adhesion receptors, such as integrin α4β1. These receptors interact with adhesion molecules expressed on the conjunctival
endothelium and may be a target to treat this disease. We synthesized DS-70, a novel α/β-peptidomimetic α4 integrin antagonist,
to prevent the conjunctival infiltration of immune cells and clinical symptoms in a model of allergic conjunctivitis.
EXPERIMENTAL APPROACH
In vitro, DS-70 was pharmacologically characterized using a scintillation proximity procedure to measure its affinity for α4β1
integrin, and its effect on cell adhesion mediated by different integrins was also evaluated. The effects of DS-70 on vascular cell
adhesion molecule-1 (VCAM-1)-mediated degranulation of a human mast cell line and an eosinophilic cell line, which both
express α4β1, and on VCAM-1-mediated phosphorylation of ERK 1/2 in Jurkat E6.1 cells were investigated. Effects of DS-70
administered in the conjunctival fornix of ovalbumin-sensitized guinea pigs were evaluated.
KEY RESULTS
DS-70 bound to integrin α4β1 with nanomolar affinity, prevented the adhesion of α4 integrin-expressing cells, antagonized VCAM-1-
mediated degranulation of mast cells and eosinophils and ERK 1/2 phosphorylation. Only 20%was degraded after an 8 h incubation
with serum. DS-70 dose-dependently reduced the clinical symptoms of allergic conjunctivitis, conjunctival α4 integrin expression
and conjunctival levels of chemokines and cytokines in ovalbumin-sensitized guinea pigs.
CONCLUSIONS AND IMPLICATIONS
These findings highlight the role of α4 integrin in allergic conjunctivitis and suggest that DS-70 is a potential treatment for this
condition.
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Introduction
Allergic conjunctivitis includes a variety of ocular inflamma-
tory diseases that are mainly caused by type 1 hypersensitiv-
ity reactions related to the preferential generation of IgE
antibodies (Baiula and Spampinato, 2014). The early phase
reaction occurs when allergens recognize IgE antibodies
bound to the high-affinity receptor for the Fc region of IgE
on conjunctival mast cells. This event triggers mast cell de-
granulation, histamine release and the generation of prosta-
glandins, leukotrienes, cytokines and chemokines, causing
ocular itching and hyperaemia. Additional symptoms in-
clude swelling of the surrounding eyelids, chemosis and tear-
ing. The early phase reaction leads to a late phase after 6–12 h
that is sustained by T-cell-dependent processes through the
production of cytokines and chemokines that mediate the re-
cruitment and conjunctival infiltration of eosinophils and
other immune cells (Choi and Bielory, 2008). This latter event
requires the interaction between leukocyte surface-adhesion
receptors, such as integrins and selectins, and adhesion
molecules expressed on the conjunctival endothelium, such
as intercellular adhesion molecule-1 (ICAM-1) (Oh et al.,
1999) and vascular cell adhesion molecule-1 (VCAM-1)
(Baiula et al., 2012). Increased levels of cell adhesion mole-
cules on the microvasculature and factors that regulate these
molecules may perpetuate inflammation in allergic conjunc-
tivitis (Okada et al., 2005).
Integrin α4 associates with a β1 or β7 subunit on leuko-
cytes to form the integrin heterodimers α4β1 and α4β7 that
mediate cell adhesion to VCAM-1 and fibronectin (FN)
and behave as both adhesion and signalling molecules
(Kummer and Ginsberg, 2006). Integrin α4β7 is predomi-
nantly expressed in a subpopulation of CD4(+) CD45RA(+)
T-cells, which have been shown to preferentially home to
the gut through interactions with mucosal addressin cell ad-
hesion molecule-1 (MAdCAM-1) (Wright et al., 2002).
Integrin α4β1 is expressed in mast cells, which contributes
to the recruitment and influences migration and functional
responses (Hallgren and Gurish, 2011). This integrin is also
expressed on eosinophils (Barthel et al., 2008), mediating
their activation and infiltration in inflamed tissues
(Ahmadzai et al., 2015), including the conjunctiva (Abu
el-Asrar et al., 1997; Baiula et al., 2012). Studies using mono-
clonal antibodies have confirmed that α4 integrin contributes
to eosinophil recruitment in allergic inflammatory diseases
(Ebihara et al., 1999; Fukushima et al., 2006). Based on these
findings, the blockade of α4β1 integrin may represent a useful
therapeutic strategy to treat allergic eye diseases. Current
therapies for allergic conjunctivitis mainly include antihista-
mines andmast cell-stabilizing agents that only alleviate clin-
ical symptoms, or glucocorticoids whose use is limited by
adverse effects (Abelson et al., 2015). Therefore, safer and
more effective drugs are required to treat allergic eye diseases
(Baiula and Spampinato, 2014).
Low MW antagonists of integrin α4 decrease airway in-
flammation in animal models of allergic asthma (Cortijo
et al., 2006; Kenyon et al., 2009). Furthermore, topical admin-
istration of an α4 integrin antagonist improves ocular surface
inflammation in a murine model of dry eye (Ecoiffier et al.,
2008) and in established ocular surface disease associated
with Sjögren’s syndrome (Contreras-Ruiz et al., 2016). The
efficacy of α4 integrin antagonists in treating allergic conjunc-
tivitis has been poorly explored. Drugs are frequently admin-
istered topically in the conjunctival fornix to treat this
pathology (Baiula and Spampinato, 2014), and low MW α4
antagonists are suitable for administration via this route.
In the present study, we report the synthesis of two
novel hybrid α/β-peptides and their pharmacological charac-
terization as potent and selective α4 integrin antagonists. Re-
cently, we described a series of α4β1 integrin antagonists
based on a β-amino acid central core, an α4 integrin-targeting
diphenylurea moiety and a moiety carrying a β1-targeting
acidic functionality at the C terminus flanked by an
aromatic substituent (Dattoli et al., 2014; De Marco et al.,
2015). The β-amino acids were chosen to increase peptide sta-
bility and for the conformational control exerted on the
overall structure (De Marco et al., 2016). Following
these early investigations, we synthesized the novel hybrid
α/β-peptidomimetics DS-70 and DS-23, which include a (D)-
configured β2-proline (the D configuration of this β-residue
corresponds to the S absolute stereochemistry). Similar to
the reference compound BIO1211, DS-70 showed a linear
sequence completed by o-methylphenylureaphenylacetyl
(MPUPA) and a simple glycine. In contrast, DS-23 represented
the partially retro analogue of DS-70, since the β-amino acid
central core was connected to 1-(4-(aminomethyl)phenyl)-3-
(O-methyl)urea (AMPUMP) and to the diacid equivalent of
glycine (Figure 1). Indeed, retro-peptide sequences showed
higher efficacy against α4β1 integrins compared to the corre-
sponding normal sequences in our previous studies (Dattoli
et al., 2014; De Marco et al., 2015).
Pharmacological characterization of these novel com-
pounds was performed in vitro using a scintillation proximity
procedure tomeasure their affinity for α4β1 integrin, and their
effects on cell adhesion mediated by this integrin were also
evaluated. DS-70 was the most potent compound and was
assayed in VCAM-1-mediated degranulation of HMC 1.1
cells, a human mast cell line, and EoL-1 cells, a human eosin-
ophilic leukaemia cell line, both of which express α4β1
integrin (Sperr et al., 1992; Jung et al., 1994). Furthermore,
DS-70 antagonized VCAM-1-mediated phosphorylation of
ERK 1/2 in Jurkat E6.1 cells. Finally, the effects of topical
treatment with DS-70 on a guinea pig model of allergic con-
junctivitis were evaluated. DS-70 dose-dependently reduced
clinical aspects of allergic conjunctivitis, conjunctival mast
cell and eosinophil infiltration, α4 integrin expression and
levels of mRNAs for IL-1β, IL-8 (CXCL8), CCL5 and
CCL11. Protein levels of these latter chemokines were also
measured. To the best of our knowledge, this report is the first
to describe a low MW compound that acts as an effective an-
tagonist of α4 integrin, following direct administration in the
conjunctival fornix in a model of allergic conjunctivitis.
Methods
General procedure for the synthesis of
peptidomimetics
Standard chemicals and the protected amino acids were ob-
tained from commercial sources and used without any purifi-
cation. The purity of intermediates and final products were
analysed by reverse-phase (RP)-HPLC, performed on Agilent
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1100 series apparatus, equipped with a RP column
Phenomenex (Torrance, CA, USA) No 00D-4439-Y0 Gemini
3 μmC18 110 Å, LC column 100 × 3.0 mm; diode-array detec-
tion was set at 210 nm. Mobile phase description: gradient
from 0.1% formic acid (0.1 mL·100 mL1) in H2O/acetoni-
trile (9:1) up to formic acid (0.1 mL·100 mL1) in H2O/aceto-
nitrile (2:8) in 20 min, flow rate = 1.0 mL·min1. Semi-
preparative RP-HPLC utilized an Agilent 1100 series appara-
tus (Agilent, Technologies, Waldbronn, Germany), equipped
with a RP column ZORBAX No 977150-102 Eclipse XDB C18
PrepHT cartridge 21.2 × 150 mm, 7 μm (Agilent Technolo-
gies). Mobile phase description: gradient from trifluoroacetic
acid (TFA; 0.1 g·100 mL1) in H2O/acetonitrile (8:2) to TFA
(0.1 mL·100 mL1) in acetonitrile (100%) in 10 min, flow
rate = 12 mL·min1. Electrospray ionization MS analysis
was performed on a HP mass spectrometer MSD 1100
detector (Agilent Technologies) with single quadrupole.
The procedures under microwave irradiation utilized
the microwave oven Micro-SYNTH microwave labstation
(Milestone Inc., Shelton, CT, USA) and temperature was
controlled by using a built-in advanced fibre optic automatic
control. 1H NMR analysis was performed on an apparatus
Varian Gemini 400 MHz (Agilent Technologies); peptide
samples were dissolved in DMSO-d6 to the final concentra-
tion of 0.01 M and analysed in 5 mm tubes at room temper-
ature. Solvent suppression of residual moisture required the
standard ‘PRESAT’ solvent presaturation procedure; chemi-
cal shifts (δ) are expressed as p.p.m. DMSO was used as an
internal standard, by setting δH = 2.50 p.p.m. The following
abbreviations are used: s, singlet; d, doublet; t, triplet; dd,
double doublet and m, multiplet. The assignment of all res-




resin (Sigma-Aldrich, Milan, Italy; 0.5 g, amino acid
load = 0.4–0.8 mmol·g1 according to the manufacturer)
was placed into a syringe equipped with a frit.
Fmoc deprotection. The Fmoc protecting group was cleaved
in 2 min by treatment with 20% piperidine in
dimethylformamide (DMF) (5 mL) while bubbling nitrogen,
under microwave irradiation (irradiation power = 40 W,
internal reaction temperature = 45°C; see above). The resin
was filtered and washed with CH3OH (5 mL), DMF (5 mL) and
CH2Cl2 (5 mL) in sequence. The cleavage procedure and
washes were repeated twice as described above. The
deprotectionwas qualitatively assessed by a positive Kaiser test.
Coupling. The acid-partner (0.9 mmol) was dissolved in
DMF (6 mL) at room temperature, in the presence of
hydroxybenzotriazole (HOBt) (0.9 mmol) and N,N0-
dicyclohexylcarbodiimide (DCC) (0.9 mmol). After stirring
for 5 min, the mixture was added to the resin pre-swollen in
CH2Cl2 (5 mL). The suspension was mechanically shaken
for 10 min under microwave irradiation. Then, the resin was
filtered and washed three times with the same solvents as
described in the paragraph above. The coupling was
assessed by the Kaiser test. The repetitive deprotection and
Figure 1
Structures of the N-to-C-terminus ‘straight’ sequence DS-70 of its partially retro-analogue DS-23 and the well-known α4β1 antagonist BIO1211,
showing a first inversion of the sequence between the diphenylurea group and the C-to-N oriented β2-Pro and a second inversion between the
latter and the malonate.
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coupling steps were carried out according to the same
protocols and workup procedures (Figure S1A).
Peptide cleavage. The peptidyl-resin obtained according to
the previous protocol was pre-swollen in CH2Cl2
(3 mL) and treated with a 90:5:5 mixture of TFA/H2O/
triisopropylsilylether (10 mL), plus phenol (50 mg),
and the mixture has mechanically shaken at room
temperature for 2 h. Subsequently, the cocktail was filtered
to recover the peptide, and the unloaded resin was washed
with 20% TFA in diethyl ether (5 mL), CH2Cl2 (5 mL) and
CH3OH (5 mL) in sequence. The filtrates were collected; the
volatiles were removed with a moderate nitrogen flow at
room temperature. The solid residue was suspended in ice-
cold diethyl ether to favour peptide precipitation. The
crude peptide was triturated and collected by centrifugation
at 2000× g for 10 min.
The peptide was isolated (78% yield) by semipreparative
RP-HPLC, and purity was assessed by analytical RP-HPLC
(98%). The correct compositions were determined by
electrospray impact MS (ESI-MS) analyses. DS-70 was
analysed by 1H NMR spectroscopy. 1H NMR (3:1 deuterated
chloroform/DMSO-De6, 400 MHz) δ (the spectrum shows
two sets of signals in 1:1 ratio, relative to conformers A
and B around the amide bond which precedes β-Pro):
1.82–2.03 (m, 2HA+B, β-ProH4A+B), 2.05 (s, 3HA+B, MeA+B),
2.78 (m, 1HA, β-ProH3A), 2.86 (m, 1HB, β-ProH3B), 3.16 (m,
1HB, β-ProH5B), 3.24 (m, 1HA, β-ProH5A), 3.33–3.39 (m,
2HA, β-ProH2A + β-ProH5A), 3.39–3.49 (m, 2HA+B + 3HB,
2xCH2COA+B + 1x β-ProH5B + 2x β-ProH2B), 3.54 (dd,
J = 8.0, 13.6 Hz, 1HA, β-ProH2A), 3.70 (d, J = 4.8 Hz, 2HA+B,
GlyH αA+B), 6.73 (t, J = 7.2 Hz, 1HA+B, ArH40A+B), 6.83–6.97
(m, 4HA+B, ArH30A+B + ArH50A+B + ArH2A+B), 7.19 (d,
J = 7.6 Hz, 2HA+B, ArH3A+B), 7.22 (s, 1HA+B, ureaNHA+B), 7.62
(d, J = 8.0 Hz, 1HA+B, ArH60A+B), 8.37 (s, 1HA+B, ureaNHA+B),
9.20 (br.s, 1HA+B, COOHA+B). MS m/z [M + 1] calculated for
C23H26N4O5: 439.19; found: 439.30.
BIO1211 (N-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]-
phenyl]acetyl]-L-leucyl-L-aspartyl-L-valyl-L-proline) (Figure 1)
was prepared adopting the above-described procedure.
Purity evaluated by analytical RP-HPLC was 98%. MS
m/z [M + 1] calculated for C36H48N6O6: 709.35; found:
709.40.
Synthesis of DS-23
Boc (tert-butyloxycarbonyl)-β-Pro (1.0 mmol) was dissolved
in 4:1 CH2Cl2/(5 mL) in the presence of HOBt (1.1 mmol)
and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexauorophosphate (HBTU; 1.1 mmol), and the mixture
was stirred at room temperature under an inert atmosphere
for 5 min. Thereafter, AMPUMP-TFA salt (1.1 mmol) was
added at room temperature while stirring, followed by N,
N-diisopropylethylamine (DIPEA; 2.2 mmol). The mixture
was stirred for 10 min under microwave irradiation (see
above). The mixture was diluted with CH2Cl2 (40 mL) and
washed with 0.5 M HCl (5 mL) and with saturated solution
of NaHCO3 (5 mL). The organic layer was dried over Na2SO4,
and solvent was removed at reduced pressure. The protected
intermediate was isolated (75%) by flash chromatography
over silica-gel (eluent: 100% ethyl acetate).
Subsequently, the Boc group was removed by treatment
with 25% TFA in CH2Cl2 (10 mL). The mixture was subjected
to moderate nitrogen flow at room temperature until a solid
residue was obtained.
The resulting TFA salt was utilized without purification
and coupled with 3-(benzyloxy)-3-oxopropanoic acid under
the same conditions as described above, following the same
work up, including the isolation of the intermediate.
The benzyl ester was removed by treatment with H2
palladium on carbon in ethanol for 4 h (Figure S1B) at room
temperature. The mixture was filtered over Celite® (Sigma-
Aldrich), and the filter was washed with ethanol (10 mL).
After evaporation of the collected ethanol layers at reduced
pressure, the final purification of the residue was accom-
plished with semi preparative RP-HPLC, and purity was deter-
mined by analytical RP-HPLC (97%; see the General
procedure for the synthesis of peptidomimetics). MS m/z
[M + 1] 439.2; calculated for C23H26N4O5: 439.19; found:
439.20.
Animals
All animal care and experimental protocols complied with
the EU Directive 2010/63 and the D. Lgs. 116/92 of the Italian
legislation in effect at the time of the study (June and July,
2012). The Scientific Ethics Committee on Animal Experi-
mentation of the University of Bologna approved the experi-
mental protocol adopted (protocol n. 31331-X/10; July 22,
2011). This study followed the editorial on experimental de-
sign and analysis in pharmacology (Curtis et al., 2018). Ani-
mal studies are reported in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015).
Fifty male Hartley albino guinea pigs (250–300 g, 6- to 8-
week-old) obtained from Charles River Laboratories Italia
(Calco, Italy) were used. Animals were housed in groups of
five to six in a controlled environment at 22–24°C and hu-
midity 60–62%, with a 12 h light/dark cycle and access to
food (Teklad Global Guinea Pig Diet 2040) and tap water ad
libitum. All efforts were made to minimize animal suffering.
The cages contained soft bedding and environmental enrich-
ment for welfare purposes, and the animals were allowed to
acclimatise to this environment for 7–9 days after arrival in
the unit before use.
Ovalbumin sensitization
Animals were sensitized to chicken-derived ovalbumin using
aluminium hydroxide as an adjuvant to promote an IgE-
mediated conjunctival allergic response (Groneberg et al.,
2003). Guinea pigs were randomly divided into eight experi-
mental groups of five animals per group. Group sizes were
based on our earlier studies with the ovalbumin-challenge
model showing a significant and reproducible conjunctival
inflammation with eosinophil infiltration (Qasem et al.,
2008; Baiula et al., 2011). Five groups were sensitized on days
1, 7 and 14 by an i.p. injection of 200 μg of ovalbumin with
40 mg of aluminium hydroxide suspended in 200 μL of
saline, as previously reported (Qasem et al., 2008), and three
groups received an i.p. injection of 200 μL of saline (control).
On day 21, sensitized guinea pigs and one control group
received 30 μL of saline containing 3 mg of ovalbumin in
the conjunctival fornix of both eyes; 30 and 10 min before
ovalbumin challenge, three groups of sensitized animals
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received 30 μL of a vehicle containing 0.01, 0.05 and 0.1%,
(w/v) of DS-70, respectively, in the conjunctival fornix of
both eyes and gently closing the eyelid to prolong the drug
residence time in the conjunctiva (Awwad et al., 2017). An-
other group of ovalbumin-sensitized guinea pigs and a con-
trol group received 30 μL of vehicle per eye 30 and 10 min
before ovalbumin challenge. The second control group re-
ceived 30 μL of 0.1 g·100 mL1 DS-70 in both eyes 30 and
10 min before topical saline administration. The last control
group received dexamethasone (30 μL of 0.1 g·100 mL1;
0.1% ), 30 and 10min before topical saline administration. Fi-
nally, an ovalbumin-sensitized guinea pig group received
30 μL of 0.1% dexamethasone in both eyes 30 and 10 min be-
fore ovalbumin challenge.
Clinical conjunctival symptoms were rated in both eyes
using the following scale: 0, no symptoms; 1, slight conjunc-
tival redness with or without tears; 2, mild conjunctival red-
ness with or without tears and mild chemosis; 3, mild
conjunctival redness with or without tears and moderate
chemosis; 4, severe conjunctival redness with tears and par-
tial lid eversion; 5, severe conjunctival redness with tears
and lids more than half closed. Photographs of both eyes
were taken to evaluate the clinical score 30 min before
ocular treatments and 1, 2, 4, 6 and 24 h after ovalbumin ad-
ministration. The animals were killed 24 h after ovalbumin
challenge. Guinea pigs were sedated, prior to ovalbumin chal-
lenge, with a mixture of Ketalar® and Rompun® (32 mg·kg1
Ketalar and 2.3 mg·kg1 Rompun), given i.p.. The animals
were killed 24 h later with 100 mg·kg1 of pentobarbital, i.p..
Tarsal conjunctiva were carefully excised from both eyes
and divided into separate samples for subsequent investiga-
tions. One samplewas fixedwith a 10%buffered paraformalde-
hyde solution and embedded in paraffin. Slices (6 μm thick)
were stained to determine the number of mast cells and
eosinophils and to perform immunohistochemical (IHC)
assays. Other samples were collected to quantify eosinophil
peroxidase activity, cytokine and chemokine mRNA levels.
Conjunctival absorption of DS-70
To evaluate the conjunctival absorption of DS-70 in guinea
pigs, this compound (30 μL of 0.1 g·100 mL1) was adminis-
tered in the right eye, whereas the contralateral eye was
treated with the vehicle used to dissolve DS-70. Ttwo treat-
ments were given, 30 min apart. Guinea pigs (five per group)
were killed with pentobarbital (100 mg·kg1 i.p.), 1 h or 6 h
after the first treatment. Tarsal conjunctiva was collected,
weighed and processed as described (Iyer et al., 2015) to ex-
tract DS-70. Internal standard was levocabastine hydro-
chloride (0.5 mg·mL1). DS-70 was quantified using a
standard curve (84 μg·mL1–27 ng·mL1). Detection of DS-
70 and levocabastine was carried out as previously described
in the paragraph ‘Synthesis of DS-70’.
Validity of animal species and model selected
for study
Allergic conjunctivitis is a localized pathological condition
that is observed as the only or dominant presentation of an
allergic sensitization when an allergen irritates conjunctiva
or is associated with rhinitis. Ocular symptoms, which are es-
timated to be present in more than 75% of allergic patients,
include itching, tearing, redness and swelling, but no pain.
Signs and symptoms of allergic conjunctivitis involve a com-
plex series of immunological mechanisms initiated by the
sensitization to a novel allergen. Upon re-exposure, the anti-
gen is recognized by allergen-specific IgE receptors located on
conjunctival mast cells, leading to their activation and de-
granulation (Baiula and Spampinato, 2014). We have
adopted a guinea pig model of allergen exposure and chal-
lenge (Qasem et al., 2008; Baiula et al., 2014) that is similar
to models used in the clinic.
Conjunctival manifestations of ocular allergy are caused
by immune cell activation and the release of allergic media-
tors on the ocular surface that have been detected in animal
models and in patients (Groneberg et al., 2003). Several in-
flammatory intermediates, such as proteins, cytokines and
chemokines, have been proposed as potential biomarkers of
allergic conjunctivitis in patients (Irkec and Bozkurt, 2012)
and have been assayed in animal models (Baiula et al.,
2014). In contrast to the large amount of experimental stud-
ies on allergic asthma, few experimental studies have used
models of allergic eye diseases. Guinea pigs are among the
major laboratory animal species employed for the assessment
of ocular allergies, as they have proved to be a valid model to
assess the anti-allergic effects of established and newly devel-
oped compounds, which are mainly administered directly
into the conjunctival sac (Groneberg et al., 2003).
Cell culture
All cell lines were purchased from the ATCC (Rockville, MD,
USA) except as otherwise specified. Cell culture medium of
each cell line is described in detail in Table S2. HEL cells were
a kind gift from C. Prata and L. Zambonin (Mayo Foundation
for Medical Education and Research, Rochester, MN, USA);
MCF7 and HT-29 cells were a kind gift from Prof. N. Calonghi
(Mayo Foundation for Medical Education and Research,
Rochester, MN, USA). D283 cells were kindly donated by Prof.
G. Cenacchi (Mayo Foundation for Medical Education and
Research, Rochester, MN, USA). RPMI 8866 cells were a kind
gift from Prof. A. Santoni (Mayo Foundation for Medical
Education and Research, Rochester, MN, USA); this cell line
were usually kept in 50 mL of culture medium and allowed
to form large clumps. HMC 1.1 cells were kindly provided
by Prof. J. H. Butterfield (Mayo Foundation for Medical
Education and Research, Rochester, MN, USA). Cells were kept
at 37°C under 5% CO2 humidified atmosphere. As regards
K562 and HL60 cells, 40 h in advance of the adhesion assays,
they were treated with phorbol 12-myristate 13-acetate
(Sigma-Aldrich) in a concentration of 25 and 40 ng·mL1
respectively. This treatment induced cell differentiation and
increased expression of α5β1 and αMβ2 integrins on the cell
surface (Baiula et al., 2016). Integrin expression in the cell
lines noted above has been previously described (Erle et al.,
1994; Baiula et al., 2016) and is summarized in Table S2.
Scintillation proximity assay
We modified a scintillation proximity assay (SPA) previously
developed in our laboratory (Qasem et al., 2008) to detect
competitive binding of the tested compound to soluble
[125I]-human FN (MW approximately 440 kDa) bound to an
antibody-captured integrin α4β1 complex. α4β1 integrin was
extracted from Jurkat E6.1 cells and purified by affinity
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chromatography, following a procedure to extract membrane
proteins (Qasem et al., 2008). The experiments were carried
out in scintillation vials kept in the dark; an aliquot of cell el-
uate containing approximately 100 μg of α4β1 integrin was
added together with increasing concentrations of the tested
compounds for 90 min at room temperature. Then, the rabbit
anti-human α4 integrin antibody was added for 1 h at 4°C.
Thereafter, the beads coated with the anti-rabbit IgG anti-
body (400 ng) were added, and the mixture was incubated
for 2 h at 4°C. Finally, we added [125I]-FN (105 counts per
minute) to the vials that were then incubated for 24 h at room
temperature on a shaker. Non-specific binding was deter-
mined in the presence of the specific α4β1 integrin antagonist
BIO1211 (100 mM). Bead-associated radioactivity was mea-
sured using a LS 6500 multipurpose scintillation counter
(Beckham Coulter, Fullerton, CA, USA). The concentration
of the compounds causing 50% inhibition of binding of
[125I]-human FN to α4β1 integrin was calculated (IC50).
Cell adhesion assays
The assays were performed as previously described (Tolomelli
et al., 2015; Baiula et al., 2016). SK-MEL-24, K562, D283 and
HT-29 cells were seeded in 96-well plates coated by passive
adsorption with FN (10 μg·mL1) overnight at 4°C. For MCF7,
HEL and HL60 cells, the plates were coated with fibrinogen
(10 μg.mL1). In adhesion assays carried out with Jurkat
E6.1, EoL-1 and HMC 1.1 cells, plates were coated with
VCAM-1 (2 μg·mL1) or FN (10 μg·mL1). Alternatively, Jurkat
E6.1 cell adhesion assays were performed in plates coated with
ICAM-1 (2 μg·mL1). A saturation curve for each ligand was
plotted to establish the best signal-to-noise ratio. Non-specific
hydrophobic binding sites were blocked, for 30 min at 37°C,
by incubation with BSA (1 g·100 mL1) dissolved in HBSS.
The number of adherent cells was calculated by compari-
son with a standard curve prepared in the same plate using
known concentrations of labelled cells. The effect of
antagonists was evaluated by the reduction in adherent cells
in comparison to the controls. Adhesion assays were also
carried out in the presence of an anti-human α4 integrin anti-
body (5 μg·mL1). Experiments were carried out in quadrupli-
cate and repeated at least five times.
Western blot analysis
Jurkat E6.1, EoL-1 and HMC 1.1 cells were cultured for
16/18 h in medium containing a reduced amount of FBS
(1 g·100 mL1). Then, 3 × 106 cells were pre-incubated with
different concentrations of DS-70 for 60 min and then seeded
for 1 h in VCAM-1-(2 μg·mL1) coated plates and lysed on ice
using a mammalian protein extraction reagent (M-PER;
Pierce, Rockford, IL, USA) in the presence of a phosphatase
inhibitor cocktail. Protein extracts were quantified using a
BCA protein assay kit (Pierce, Rockford, IL, USA), heated for
5 min at 95°C, and equal amounts of the samples were sepa-
rated by 12% SDS-PAGE gel, transferred onto nitrocellulose
membranes and immunoblotted with the indicated antibod-
ies. Incubations with anti-phospho-ERK 1/2 (1:1000) (Cell
Signaling Technology, Danvers, MA, USA) or anti-total
ERK1/2 antibodies (1:2500) (Cell Signaling Technology) took
place overnight at 4°C in the presence of BSA (5 g·100 mL1)
in Tris buffered-saline containing Tween-20 (0.1 g·100mL1).
After washing, anti-rabbit HRP-conjugated secondary
antibodies (Santa Cruz Biotechnology, Dallas, TX, USA) were
added tomembranes for 1.5 h at room temperature. Protocols
for image acquisition and analysis have been previously de-
scribed (Bedini et al., 2008).
HUTS-21 monoclonal antibody binding
Flow cytometry analysis was carried out in accordance to pro-
tocols previously described (Baiula et al., 2016). Jurkat E6.1
cells were suspended in BSA/HBSS (106 cells·mL1; 100 μL per
sample) and kept at 37°C. Then, VCAM-1 (2 μg·mL1) and dif-
ferent concentrations of DS-70 (104–1010 M) were added to
the cells for 30min. Thereafter, phycoerythrin (PE)-conjugated
HUTS-21 monoclonal antibody (mAb) (PE mouse anti-human
CD29 antibody, Becton Dickinson Italia, Milan, Italy) (20 μL
per sample) was added for 45 min at room temperature to as-
sure an optimal labelling. After two washes with BSA/HBSS,
the cells were suspended in PBS, and 10 000 cells per sample
were analysed in a Guava®EasyCyte Flow Cytometer (Merck,
Milan, Italy). The data are presented as mean channel fluores-
cence, at each concentration of DS-70. Control cells were ex-
posed to an isotype control mAb (PE mouse IgG2a, k isotype
control clone G155-178, Becton Dickinson Italia), and the
measured fluorescence intensity was considered as non-
specific binding and subtracted from total fluorescence.
Flow cytometry
For the detection of cell surface α4 integrin, cells were col-
lected from culture plates, washed two times with PBS and in-
cubated with a FITC-labelled anti-α4 antibody (FITC Mouse
anti-human CD49d, Becton Dickinson Italia) (5 μL per sam-
ple) for 45 min at room temperature. Flow cytometry was per-
formed using a Guava EasyCyte Flow Cytometer (Merck).
To detect any apoptosis and/or necrosis in Jurkat E6.1,
EoL-1 and HMC 1.1 cell lines exposed to DS-70, 75 000 cells
per well were incubated with the compound (104 M) for
6 h at 37°C. A mixture 1:1 of complete medium/Guava Nexin
Reagent (Merck) was added to cells, following the manufac-
turer’s instructions for staining. Viable cells [annexin V-PE
and 7-aminoactinomycin D (7-AAD) negative], early apopto-
tic cells (annexin V-PE positive and 7-AAD negative), and late
stage apoptosis or necrotic cells (annexin V-PE and 7-AAD
positive) were separately counted. At least 10.000 cells per
sample were acquired.
Cell degranulation assays
Degranulation assays were carried out in HMC 1.1 and EoL-1
cells. β-Hexosaminidase, a marker of mast cell degranulation,
was quantitated to measure HMC 1.1 degranulation as these
cells exhibit many characteristics of tissue mast cells
(Sundström et al., 2003). Each experiment was carried out in
triplicate and repeated at least five times. Values are expressed
as percentage of degranulation and derived from the following
equation: (experimental β-hexosaminidase release  vehicle
β-hexosaminidase release)/(Triton X-100 β-hexosaminidase
release  vehicle control β-hexosaminidase release) × 100.
The o-phenylenediamine method previously described by
us (Qasem et al., 2008) was used to measure eosinophil perox-
idase release. Measurement of absorbance was performed at
490 nm using a Victor2 multilabel counter (PerkinElmer, Mi-
lan, Italy). Each experiment was carried out in triplicate and
repeated at least five times.
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Histological and immunofluorescent detection
of mast cells and eosinophils
Degranulatedmast cellswere evaluated in photographs of three
random sections (6 μm thick) per eye obtained from tarsal
conjunctiva specimens, stained in May–Grünwald–Giemsa
solution (Sigma-Aldrich) for 60 min at room temperature and
detectedwith a lightmicroscopeNikon Eclipse E800 (Nikon In-
struments S.p.a., Florence, Italy) (400× magnification).
Histological sections of tarsal conjunctiva (6 μm thick)
were processed to determine eosinophil infiltration using a
classical Luna’s protocol (Baiula et al., 2011). The sections were
immersed in haematoxylin-Biebrich scarlet solution for 5 min,
dipped (~8×) in 1% acid alcohol (Sigma-Aldrich) and rinsed in
water. Sections were then dipped (~5×) in lithium carbonate
(0.5 g·100 mL1) until turned blue and washed in running
tap water. Pictures were taken of three random sections per
eye, and eosinophils were detected under light microscopy
(500× magnification). Eosinophils or degranulated mast
cells were counted and expressed as number of cells·mm2.
For co-labelling experiments, conjunctival sections were
incubated with blocking solution containing BSA
(1 g·100 mL1), glycine (22.5 mg·mL1) and Tween20
(0.1 g·100 mL1) in PBS for 30 min. Then, tissues were incu-
bated with primary antibody overnight at 4°C in a humidified
chamber; primary antibody included: rabbit polyclonal anti-
integrin α4 antibody (diluted 1:100; Abcam, Cambridge,
UK), mouse anti-human mast cell tryptase antibody (clone
AA1, diluted 1:200; BioRad, Milan, Italy) and mouse anti-
human eosinophil major basic protein (MBP) antibody (clone
BMK13, diluted 1:200, EMDMillipore, Merck S.p.a., Milan, It-
aly). Conjunctival sections were simultaneously labelled with
mixtures of α4 integrin antibody with either anti-tryptase or
anti-MBP antibody. After three washes in PBS, tissues were in-
cubated with a mixture of secondary antibodies: goat anti-
mouse antibody labelled with AlexaFluor 488 and goat anti-
rabbit antibody labelled with AlexaFluor 568, both diluted
1:500. Digital images were captured using a Nikon C1s
(Nikon Instruments S.p.a., Florence, Italy) confocal laser-
scanning microscope. Anti-human mast cell tryptase and
anti-human MBP antibodies have already been employed to
label guinea pigs tissues.
Eosinophil peroxidase assay
In separate conjunctival specimens, eosinophil peroxidase
activity was assayed as previously described (Qasem et al.,
2008). The tissues were homogenized with 50 mmol·L1
Tris–HCl buffer (pH 8.0) on ice, and after adding 50mmol·L1
Tris–HCl buffer and 0.1% Triton X-100, homogenates were
placed in an ice bath for 1 h. Then, the substrate solu-
tion (50 mmol·L1 Tris–HCl buffer containing 0.1% Tri-
ton X-100, 1 mmol·L1 o-phenylenediamine, 3 mmol·L1
KBr and 0.5 mmol·L1 hydrogen peroxide) was added to sam-
ples and incubated at 37°C for 10 min. The reaction was
stopped with 4 mol·L1 H2SO4. Absorbance was measured
using a spectrophotometer at 490 nm. The oxidation of
o-phenylenediamine, in the presence of hydrogen peroxide
and KBr, was used to measure the peroxidase-mediated catab-
olism of hydrogen peroxide. One unit corresponds to 1 mmol
of hydrogen peroxide decomposed in 10 min. Results are
expressed as mU of enzyme·mg1 wet tissue.
IHC analysis
Slices prepared from tarsal conjunctiva specimens were sub-
jected to deparaffination in xylene and rehydration in serial
dilutions of ethanol. Antigen retrieval step was done in cit-
rate buffer (pH 6.0) for 20 min. Sections were washed three
times in Tris-buffered saline containing Tween-20
(0.025 g·100 mL1) (Sigma-Aldrich).
Complete staining was achieved by means of a specific
HRP/DAB detection kit (Abcam). The reagents constitute a la-
belled streptavidin-biotin immuno-enzymic antigen detec-
tion system. Briefly, after slice incubation with a protein
blocking buffer (Abcam), sections were incubated overnight
at 4°C with primary antibodies (100 μL per sample) for
CCL11 or CCL5 (Abcam; diluted 1:250) or α4 integrin (Becton
Dickinson; diluted 1:500). Slices were incubated with bio-
tinylated goat anti-rabbit IgG to detect CCL5 and CCL11 or
goat anti-mouse IgG1 to detect α4 integrin for 10 min at room
temperature and were developed according to the manufac-
turer’s instructions. Isotype negative controls were per-
formed with an isotype-matched antibody. A mouse IgG1
(Abcam) was the negative control for integrin α4 and a rabbit
IgG polyclonal antibody (Abcam) the negative control for
CCL5 and CCL11. Anti-human antibodies for CCL5, CCL11
and α4 integrin were employed as their protein sequences
are almost completely conserved between human and guinea
pig and other researchers have previously employed those an-
tibodies in guinea pig tissues successfully.
Relevant photomicrographs were taken with a 20×
objective. The analysis was done on the basis of a validated
semiquantitative scoring method (Walker, 2006). The
resulting percentage of tissue showing positive staining is
expressed as IHC score that was assigned by two blinded re-
searchers to quantitate IHC-positively stained cells and areas,
according to five categories: 0, no staining; 1, <25% staining;
2, 25–50% staining; 3, 50–75% staining; and 4, >75%
staining.
Real time RT-PCR
Total RNA from tarsal conjunctiva specimens was extracted
employing TRI-Reagent. RNase-free DNase treatment was per-
formed for each sample, and 1 μg of RNA was converted into
cDNA using the High-Capacity cDNA Reverse Transcription
Kit (Life Technologies Italia, Milan, Italy), according to the
manufacturer’s instructions. GoTaq® qPCR Master Mix was
chosen to perform the reaction as follow: denaturation at
95°C for 10 min, followed by 40 cycles of 95°C denaturation
(20 s) and 58°C annealing (1 min). No-template controls
and DNA melting curve analysis were used as controls. For
data analysis, the threshold cycle (Ct) values were normalized
both on the basis of GAPDH content and on the values de-
rived from non-immunized guinea pigs. GAPDH, IL-8, IL-1β,
CCL11 and CCL5 primer sequences are listed in Table S1
and was first reported in Baiula et al. (2014).
Data and statistical analysis
All in vitro data are the means ± SD, of at least five indepen-
dent experiments, whereas for the in vivo experiments, five
animals per group were included and both eyes were analysed
(n = 10). Statistical comparisons were performed using one-
way ANOVA and post hoc Newman–Keuls test. The scores
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assigned to the conjunctival symptoms were non-
parametrically analysed using the Friedman test, followed
by Dunn’s post hoc comparison. Significant differences
among IHC scores were assessed by the Kruskal–Wallis test
followed by Dunn’s post hoc comparison. Data analysis and
IC50 values referring to experiments not mentioned above
were obtained using GraphPad Prism software (version 5.0;
GraphPad Software, Inc., La Jolla, CA, USA). The data deriv-
ing from HUTS-21 binding antibody were fitted using the sig-
moidal dose–response equation using GraphPad Prism.
P < 0.05 was considered significant.
Data related to the clinical conjunctival symptoms are
presented as scatter plot. As regards the data presented as
bar charts, scatter plot analysis did not reveal any unusual
or interesting aspect not obvious from the bar chart (George
et al., 2017). The data and statistical analysis comply with
the recommendations on experimental design and analysis
in pharmacology (Curtis et al., 2018).
Blinding procedures in experiments
Researchers involved in the experiments, data collectors, out-
come adjudicators and data analysts who did not participate
in the study were blinded to reduce the risk of bias. Personnel
who did not perform the experiments prepared the com-
pounds administered.
Materials
DS-70 was dissolved in a vehicle containing PEG 3350
(10 g·100 mL1) and polysorbate 80 (1 g·100 mL1) in
phosphate buffer (pH 7.0). Polyacrylamide gel, ammonium
persulfate, sodium dodecyl sulfate, Tween 20, lectin from
Triticus vulgaris, human FN, BSA, 4-nitrophenyl-N-acetyl-β-D-
glucosaminide, ovalbumin grade V, aluminium hydroxide
gel, o-phenylenediamine, hydrogen peroxide 30%, Triton-X-
100, peroxidase acidic isoenzyme fromhorseradish, RNAlater,
TRI Reagent, Phosphatase Inhibitor Cocktail 3, levocabastine
hydrochloride, pentobarbital sodium salt and citrate buffer
solution (0.09 M) were obtained from Sigma-Aldrich. Cell
culture media, PBS, FBS, HBSS, 5-chloromethylfluorescein
diacetate, RNase-free DNase and High-Capacity cDNA Re-
verse Transcription Kit were from Thermo Fisher Scientific.
M-PER was from Pierce. GoTaq qPCR Master Mix was
obtained from Promega Corporation (Madison, WI, USA).
Soluble human VCAM-1, MAdCAM-1, ICAM-1 and IL-5
were purchased from R&D Systems (Minneapolis, MN,
USA). Fibrinogen (plasminogen-depleted from human
plasma), mouse anti-human mAb against β1 subunit was
obtained from Merck. Rabbit anti-human mAb against α4
subunit was purchased from Santa Cruz Biotechnology as
well as secondary antibodies for western blot analysis
(Santa Cruz, CA, USA). Hybond-ECL nitrocellulose mem-
brane was from GE Healthcare (Chicago, USA). Black and
white 96-well clear-bottom plates were purchased from
Corning Costar (Celbio, Milan, Italy), and the other plastic
disposables were from Sarstedt (Nümbrecht, Germany). All
the other reagents were of analytical grade or the highest
purity available, purchased from Sigma-Aldrich. Rompun
was from Bayer (Milan, Italy) and Ketalar was from Parke
Davis (Milan, Italy).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al.,
2018), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2017/18 (Alexander et al., 2015, 2017).
Results
Peptide synthesis, general procedure
The linear peptides BIO1211 and DS-70 were prepared by
solid phase peptide synthesis on a Wang resin, using
Fmoc-protected amino acids, under microwave irradiation
conditions optimized by us (Gentilucci et al., 2016). The re-
moval of Fmoc group was performed by treatment with piper-
idine in DMF, under microwave irradiation for 2 min.
Coupling between each residue was carried out with the acti-
vating agents DCC and HOBt in 4:1 CH2Cl2 (dichlorometh-
ane)/DMF under microwave irradiation for 10 min. Peptide
cleavage was accomplished by treatment of the peptidyl-resin
with TFA in CH2Cl2 and scavengers. The crude products were
simply precipitated from ice-cold diethyl ether and collected
in almost quantitative yield by centrifugation.
On the other hand, the retro sequence DS-23 was
prepared in solution. AMPUMP was coupled with Boc-
protected β-Pro in solution under microwave irradiation,
with the aid of HOBt/HBTU/DIPEA. Boc deprotection of
the resulting dipeptide was done in TFA and was followed
by coupling with 3-(benzyloxy)-3-oxopropanoic acid under
the same conditions previously described. The resulting
benzyl ester was deprotected by catalytic hydrogenation,
giving DS-23 in good yield. Finally, all peptides were puri-
fied (96–98%) with semi-preparative RP-HPLC and identi-
fied by ESI-MS HPLC.
Binding affinity of α/β-peptides for human α4β1
integrin as measured by SPA and inhibition of
α4 integrin-mediated cell adhesion
The binding of the reference compound BIO1211 and the
novel hybrid α/β-peptides to α4β1 integrin was measured
using a SPA. [125I]-FN was the specific radioligand, and
α4β1 integrin was extracted from human Jurkat E6.1 cells
(endogenous expression). Western blot analyses of the α4β1
integrin extracted from cell lysates and purified by affinity
chromatography confirmed that both α4 and β1 integrin
subunits are present in the eluate employed in the assay
(Figure S2, panel A).
[125I]-FN binding was inhibited by the well-established
α4β1 integrin antagonist BIO1211 and by the novel hybrid
α/β-peptides DS-70 and DS-23 in a concentration-dependent
manner. As reported in Table 1, the most effective ligands
were DS-70 and BIO1211, which showed the lowest and su-
perimposable IC50 values.
Subsequently, we assayed the ability of hybrid α/β-
peptides to inhibit adhesion of α4β1 integrin-expressing
Jurkat E6.1 cells to VCAM-1 or FN. Jurkat E6.1 cell adhesion
to both adhesion molecules was inhibited (>95%) after treat-
ment with a specific anti-α4 antibody (data not shown). The
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reference compound BIO1211 and the hybrid α/β-peptides
DS-70 and DS-23 blocked Jurkat E6.1 cell adhesion in the
nanomolar range (Table 1).
DS-70 was more effective than DS-23 as an antagonist of
α4β1 integrin and we therefore focused our research efforts
on this compound. First, we assessed whether DS-70
inhibited the adhesion of the human mast cell line HMC
1.1 and of the human eosinophilic cell line EoL-1, both of
which mainly express α4β1 integrin, to VCAM-1 or FN. This
compound showed IC50 values similar to the values observed
in Jurkat E6.1 cells (Table 2).
The expression of α4 integrin on the surface of Jurkat E6.1,
EoL-1 and HMC 1.1 cell clones employed in this study was
confirmed using a FITC-labelled anti α4 antibody by flow cy-
tometry. As reported in Figure S3, the three cell lines express
consistent levels of this integrin on their surface. All the other
cell lines employed for cell adhesion assays, as shown in
Figure S3, do not express α4 integrin.
RPMI 8866 cells predominantly express the leukocyte
integrin α4β7, and the adhesion molecule MAdCAM-1 pre-
dominantly measures α4β7-mediated cell adhesion (Erle
et al., 1994). DS-70 was approximately eightfold less potent
in blocking cell adhesion mediated by α4β7 integrin bind-
ing to MAdCAM-1 in RPMI 8866 cells (Table 2) compared
to VCAM-1 and FN-mediated cell adhesion in EoL-1 or
HMC 1.1 cells. Furthermore, DS-70 did not inhibit cell ad-
hesion mediated by the leukocyte integrins αLβ2 and αMβ2
or by the Arg-Gly-Asp-binding integrins α5β1, αVβ3, αVβ5,
αVβ6 and αIIbβ3 (Table 2). Taken together, these results con-
firm that DS-70 may behave as a competitive antagonist of
cell adhesion molecules that preferentially bind to α4
integrin.
In vitro enzymic stability of DS-70
The in vitro stability of DS-70 in mouse serum at 37°C was
compared with BIO1211. As shown in Figure S4, BIO1211
had an approximate half-life of 0.27 ± 0.07 h (mean ± SD;
n = 5). DS-70 was more stable, and after 8 h, 21 ± 2% of its
content in serum had degraded. These data support the
hypothesis that the presence of the β-amino acid scaffold
markedly increased the enzymic stability of this
peptidomimetic.
Effects of DS-70 on VCAM-1-mediated ERK
1/2 phosphorylation
Intracellular signalling generated by the interaction of com-
ponents of the extracellular matrix with integrin α4β1 in-
volves second messengers such as ERK1/2 that contribute to
α4 integrin-mediated cell functions (Abdala-Valencia et al.,
2011). The addition of DS-70 alone to Jurkat E6.1 cells did
not cause any significant increase in ERK 1/2 phosphoryla-
tion compared to vehicle-treated cells (data not shown).
A significant increase in ERK 1/2 phosphorylation was
detected 60 min after Jurkat E6.1 cells were exposed to
VCAM-1-coated plates (2 μg·mL1). Pre-incubation with
DS-70 (1010–104 M) for 60 min, produced a concentration-
dependent decrease in VCAM-1-mediated ERK1/2 phosphor-
ylation (Figure 2A,B). DS-70 was also effective in reducing,
in a concentration-related manner, ERK 1/2 phosphoryla-
tion induced by VCAM-1 in HMC 1.1 and EoL-1 cells
(Figure S5).
Table 1
SPA binding to bead-associated α4β1 integrin and inhibition of Jurkat E6.1 cell adhesion of the reference compound BIO1211 and hybrid α/β-peptides
a
to VCAM-1 (2 μg·mL1) or FN (10 μg·mL1).






BIO1211 8.80 ± 3.4 (0.08–46.7)c 4.60 ± 3.0 (0.05–25.1) 5.50 ± 4.0 (0.09–37.6)
DS-70 8.3 ± 3.2 (0.1–37.2) 5.04 ± 0.51 (0.05–37.3) 4.3 ± 1.7 (0.04–23.4)
DS-23 47.7 ± 4.1 (4.6–161.4) 40.3 ± 7.1 (3.4–127.6) 51 ± 5.0 (4.8–192.4)
aResults were generated by measuring, in a cell-free SPA, the inhibition of [125I]-FN binding by the assayed compounds on Jurkat E6.1 cell lysates in the
presence of 10 increasing concentrations of each compound (1012–103 M) and a fixed amount of radioligand (100 000 counts per minute).
bSix independent experiments were run in quadruplicate.
Data are expressed as means ± SD (with c95% confidence limits).
Table 2







HMC-1/α4β1 VCAM-1 8.4 ± 1.9 (0.1–32.4)
c
EoL-1/α4β1 VCAM-1 9.7 ± 3.2 (1.2–38.6)









aIn a cell-based assay, the adhesion of a cell line preferentially ex-
pressing a specific integrin heterodimer to an immobilized adhesion
molecule was measured.
bSix independent experiments were run in quadruplicate.
Data are expressed as means ± SD (with c95% confidence limits).
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DS-70 binding to α4β1 integrin modulates
HUTS-21 epitope exposure in Jurkat E6.1 cells
Integrins exist in three major conformations: an inactive or
bent conformation, an intermediate-activity conformation
and a high-activity open conformation (Margadant et al.,
2011). Conformational changes in integrin subunits may be
monitored using conformation-specific antibodies that rec-
ognize a specific epitope that is exposed only in a defined
structural conformation (Luque et al., 1996). We used the
PE-conjugated HUTS-21mAb to determine whether the bind-
ing of DS-70 to α4β1 integrin alters its conformation. This
mAb recognizes a ligand-induced binding site epitope that
is masked in the inactive integrin but is exposed upon agonist
binding or partial integrin activation. The epitope recognized
by HUTS-21 has been mapped to the hybrid domain of β1
integrin (Luque et al., 1996). This mAb was added to Jurkat
E6.1 cells in the presence of VCAM-1 (2 μg·mL1), and fluo-
rescence was assayed using flow cytometry. As expected,
HUTS-21 binds to β1 integrin and exhibits increased Jurkat
cell-associated fluorescence compared to the cells exposed
to an isotype control mAb. The binding of α4β1 integrin to
its endogenous ligand VCAM-1 induces a conformational
rearrangement in the β1 subunit that exposes the HUTS-21
epitope and increases antibody binding. As shown in
Figure 2C, DS-70 (1010–104 M) concentration-dependently
reduced the exposure of the HUTS-21 epitope as it decreased
mAb binding in the presence of VCAM-1 with an IC50 of
4.33 x.108 M. DS-70 alone (1010–104 M) did not result in
any significant exposure of the mAb epitope registered as an
increase of fluorescence (data not shown). Thus, DS-70 seems
to act as an α4β1 integrin antagonist, as it favours the inactive
and/or intermediate-activity conformations of this integrin.
DS-70 inhibits VCAM-1-mediated mast cell
and eosinophil degranulation
Integrin α4 plays a crucial role in allergic reactions because it is
expressed on mast cells (Yasuda et al., 1995; Hallgren and
Gurish, 2011) and eosinophils (Barthel et al., 2008). Integrin
adhesion molecules are involved in the trafficking of inflam-
matory cells from the circulation into inflamed tissues
(Kourtzelis et al., 2017) and contribute to acute mast cell
degranulation following allergen exposure (Hojo et al.,
1998). Consistent with this latter observation, VCAM-1
(2 μg·mL1) caused significant degranulation of the human
Figure 2
DS-70 reduces, in a concentration-relatedmanner, VCAM-1-induced ERK 1/2 phosphorylation (pERK 1/2) in Jurkat E6.1 cells and VCAM-1 binding
to Jurkat E6.1 cells exposed to PE-conjugated HUTS-21 mAb. (A) Jurkat E6.1 cell extracts were assayed for pERK 1/2 by Western blotting; a repre-
sentative assay is shown. Control cells plated on VCAM-1 had a much stronger signal for pERK 1/2 than vehicle-treated cells. DS-70 reduces
VCAM-1-induced pERK1/2, whereas, at a higher concentration (104 M), it was not able to modify pERK1/2 in the absence of this adhesion mol-
ecule. (B) The results of semiquantitative densitometry analysis of the bands from five independent experiments are shown (mean ± SD); the
amount of pERK 1/2 is normalized to that of total ERK 1/2. *P < 0.05, significantly different from vehicle; #P < 0.05, significantly different from
VCAM-1. (C) Mean fluorescence intensity (MFI) due to the anti-β1 integrin mAb PE conjugated HUTS-21 plotted against different concentrations
of DS-70 added to Jurkat E6.1 cells in the presence of VCAM-1 (5 μg·mL1) was measured. Each point represents the mean ± SD of five indepen-
dent experiments carried out in triplicate. VCAM-1 administered alone was able to promote epitope exposure and a significant increase of MFI
over vehicle-treated cells exposed to PE conjugated HUTS-21 alone (MFI values were 130 ± 3 vs. 80 ± 4; n = 5. P< 0.05, significantly different from
VCAM-1 alone. Non-specific binding of an isotype control PE conjugatedmAb added to Jurkat E6.1 cells produced anMFI of 38 ± 4 (n = 5) that was
subtracted from all samples.
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mast cell line HMC 1.1, as assayed bymeasuring the release of
β-hexosaminidase into the cell supernatant. This effect was
prevented by exposing the cells to a mAb that binds to the
α4β1 integrin expressed on the cell surface.
Pretreatment with DS-70 (1010–104 M) 60 min prior to
VCAM-1 administration caused a concentration-dependent
inhibition of VCAM-1-induced mast cell degranulation
(Figure 3A).
VCAM-1 may interact with several cytokines to promote
eosinophil recruitment during the initiation phase of inflam-
mation, and the functional activation of eosinophils is char-
acterized by degranulation (Nagata et al., 1998). IL-5 plays a
fundamental role in eosinophil differentiation in the bone
marrow, as well as recruitment and activation at sites of aller-
gic inflammation (Broughton et al., 2015). Based on this pre-
mise, we found that VCAM-1 or IL-5 promote a significant
EoL-1 degranulation by measuring the release of eosinophil
peroxidase in cell culture medium. IL-5-induced release of
eosinophil peroxidase was significantly increased following
a 4 h incubation in VCAM-1-coated wells; this effect was
blocked by a mAb that binds to α4 integrin. DS-70
(1010–104 M) prevents the IL-5-induced release of eosino-
phil peroxidase from cells maintained in VCAM-1-coated
wells in a concentration-related manner whereas, when
added to control cells, DS-70 was not effective (Figure 3B).
DS-70 does not promote cell apoptosis and
necrosis
We analysed the capacity of DS-70 to induce apoptosis and
necrosis in the three cell lines used in this study: Jurkat
E6.1, HMC 1.1 and EoL-1. Cells were treated with DS-70
(104 M) for 6 h, and cell apoptosis and/or necrosis were
assessed by flow cytometry; we measured annexin V-PE fluo-
rescence using 7-AAD-induced apoptotic cells as a positive
control. As shown in Figure S6, DS-70 did not cause any sig-
nificant apoptotic cell death in the three cell lines investi-
gated. Compared with the control, the number of live cells
did not decrease, and the percentages of early apoptotic cells,
late apoptotic/secondary necrotic or damaged cells did not
change in the presence of DS-70.
DS-70 eye drops reduce allergic reactions in
guinea pigs and conjunctival α4 integrin
Guinea pigs were actively immunized via i.p. administra-
tion of ovalbumin and challenged with ovalbumin instilled
into the conjunctival sac 21 days later. One hour after chal-
lenge, during the early phase reaction, clinical observations
revealed typical early phase symptoms of allergic conjunc-
tivitis, such as tearing and discharge, conjunctival redness
and chemosis. The mean clinical score reached the maxi-
mum 2 h after allergen challenge and thereafter showed a
progressive decrease. At 24 h after challenge, the conjunc-
tiva did not present any relevant clinical symptom (Baiula
et al., 2014).
The administration of DS-70 eye drops (0.01, 0.05 and
0.1%, w/v) in the conjunctival sac of both eyes (30 μL per
eye) of ovalbumin-sensitized guinea pigs 30 and 10 min be-
fore topical ovalbumin challenge reduced inflammatory signs
observed in the early and late phases of conjunctival allergy
Figure 3
DS-70 antagonizes HMC1.1 cells degranulation and eosinophil peroxidase release from the eosinophilc EoL-1 cells. (A) In HMC1.1 cells seeded on
VCAM-1 (2 μg·mL1)-coated plates, a pronounced increase of β-hexosaminidase release is observed. DS-70 (1010–104 M) concentration-
dependently decreased β-hexosaminidase release. VCAM-1-induced β-hexosaminidase release is significantly prevented in cells treated with a
monoclonal antibody anti-α4. Degranulation is expressed as percentage of β-hexosaminidase released over total content measured in cells lysed
with Triton X-100. (B) VCAM-1 (5 μg·mL1) exposure promotes a significant increase of eosinophil peroxidase release from EoL-1 cells and ele-
vates IL-5 (50 ng·mL1)-induced release of this enzyme. DS-70 (104–1010 M) added to the cells prior to exposure to VCAM-1 and IL-5 signifi-
cantly reduces eosinophil peroxidase release. β-Hexosaminidase release caused by VCAM-1 + IL-5 is significantly prevented by pre-treatment with
a monoclonal antibody anti-α4. Data are expressed as the mean ± SD of five experiments carried out in triplicate. *P < 0.05, significantly different
from vehicle; #P < 0.05, significantly different from VCAM-1 (panel A) or VCAM-1 + IL-5 (panel B); §P < 0.05, significantly different from IL-5.
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in a dose-dependent manner. The 0.1% dose was the most ef-
fective. The topical administration of DS-70 eye drops (0.1%;
administered twice 20 min apart) in control guinea pigs sen-
sitized with saline did not cause any significant sign of dis-
comfort or any conjunctival inflammatory symptoms
(Figure 4).
A selective and sensitive LM-MS/MS method was devel-
oped for the analysis of DS-70 and the internal standard
levocabastine hydrochloride in the guinea pig conjunctiva.
Both the analyte and the internal standard had similar molec-
ular weight and ClogP values. Adopting this procedure, DS-70
administered to the conjunctival fornix (30 μL of
0.1 g·100 mL1) twice, 30 min apart, was detected in the con-
junctiva 1 h after the first treatment (7780 ± 1000 ng·g1 wet
tissue). Interestingly, conjunctival DS-70 was also detected at
lower levels, 6 h after the first treatment (3450 ± 800 ng·g1
wet tissue).
The effects of DS-70 on allergic ocular conjunctivitis
were compared to those induced by a reference drug dexa-
methasone (Figure S7). Dexamethasone eye drops (0.1%,
w/v) administered to a separate group of guinea pigs sensi-
tized and challenged with ovalbumin as described above
produced a reduction of allergic conjunctivitis, superimpos-
able on the effect elicited by DS-70 (0.1%) (Figure S7).
Figure 4
Effects of DS-70 on conjunctival symptoms induced by ovalbumin (OVA) in guinea pigs. Guinea pigs sensitized and challenged with ovalbumin
and treated with the vehicle used to dissolve DS-70 (vehicle + OVA) responded with an increase in clinical score index. Administration of DS-70
significantly counteracts, in a dose-related manner, pathological signs and improves eye appearance. Data are presented as scatter plot and refer
to the mean ± SD (five animals per group were included, and both eyes were evaluated; n = 10). *P < 0.05, significantly different from
saline + vehicle; #P < 0.05, significantly different from vehicle + OVA.
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These data are in agreement with our previous paper
(Baiula et al., 2011).
Guinea pigs were killed 24 h later, and tissues were
analysed histologically. Numerous mast cells infiltrating the
lamina propria and stroma of the conjunctiva were observed,
and most had degranulated in guinea pigs sensitized and
challenged with ovalbumin. It was possible to recognize both
metachromatic and degranulated mast cells with
May–Grünwald–Giemsa staining (Figure S8A). In contrast to
vehicle-treated guinea pigs, DS-70 caused a dose-dependent
reduction in the number of infiltrating degranulated mast
cells, and the majority were granulated mast cells (Figures 5A
and S8A).
Similarly, eosinophil infiltration and eosinophil peroxi-
dase activity, which are used as an index of the conjunctival
infiltration of eosinophils (Qasem et al., 2008), were in-
creased in specimens of tarsal conjunctiva obtained from
guinea pigs killed 24 h after antigen sensitization and chal-
lenge, whereas a notable, dose-dependent reduction in both
parameters was observed in DS-70-treated guinea pigs
(Figure 5B,C).
Exposure of ovalbumin-sensitized guinea pigs to the top-
ical challenge of ovalbumin instilled into the conjunctival
sac induced a significant increase in α4 integrin levels in sec-
tions of tarsal conjunctiva after 24 h, as measured by immu-
nohistochemistry. This increase may be a consequence of
the elevated infiltration of leukocytes, such as eosinophils ex-
pressing this integrin in the conjunctiva, including mast
cells. Interestingly, DS-70 significantly reduced α4 integrin ex-
pression in conjunctival specimens obtained from treated
guinea pigs in a dose-dependent manner (Figure 6).
Immunofluorescence analysis carried out on sections ob-
tained from tarsal conjunctiva specimens of guinea pigs sen-
sitized and challenged with ovalbumin showed a double
staining for tryptase, as marker of mast cells (Hojo et al.,
1998) and α4 integrin. Moreover, the double staining of
MBP, a marker of eosinophils (Nagata et al., 1998), and α4
integrin showed the presence of both proteins in specimens
of tarsal conjunctiva (Figure S9). Numerous cells positive for
double staining were observed, confirming that α4 integrin
is expressed on both mast cells and eosinophils localized in
conjunctival specimens (Figure S9).
DS-70 eye drops reduce conjunctival levels of
chemokine and cytokine mRNAs and protein
content of CCL5 and CCL11 in
ovalbumin-treated guinea pigs
Ovalbumin challenge in actively immunized guinea pigs in-
duced a significant elevation of the levels of mRNAs for IL-8,
IL-1β, CCL5 and CCL11, and of protein levels of CCL5 and
CCL11, in tarsal conjunctival specimens after 24 h. Pretreat-
ment with DS-70 prior to ovalbumin challenge effectively
and dose-dependently reduced the conjunctival levels of the
cytokine and chemokine mRNAs (Figure 7) as well as CCL5
and CCL11 protein levels (Figure 8).
Discussion
In our continuing investigations of small molecules possessing
the pharmacological profile of integrin antagonists, we de-
signed and synthesized two novel peptidomimetics. DS-70
possesses a β-amino acid that contributes to increased serum
stability compared to the reference α4β1 integrin antagonist
BIO1211 (Lin et al., 1999). Furthermore, this component con-
tributed to the stable conformation of the overall structure.
DS-70 prevents the adhesion of Jurkat E6.1 cells, an im-
mortalized human T lymphocyte line, EoL-1 cells, a human
Figure 5
DS-70 prevents, in a dose-dependent manner, conjunctival infiltration and degranulation of mast cells and eosinophils. (A) The number of
degranulated mast cells was evaluated in photographs taken of 10 random fields of 10 different conjunctival sections (see photomicrographs
of tarsal conjunctiva stained withMay–Grünwald–Giemsa shown in Figure S8A) and reported as percentage of degranulatedmast cells (calculated
with the following formula: DMC/MC × 100). (B) Effects of DS-70 eye drops on conjunctival eosinophil infiltration 24 h after topical challenge with
ovalbumin. Substantial eosinophil infiltration was observed in guinea pigs sensitized and topically challenged with ovalbumin. In guinea pigs sen-
sitized with ovalbumin, treated with DS-70 eye drops and challenged with ovalbumin, there was a lower, dose-related, eosinophil infiltration than
in conjunctiva of guinea pigs treated with ovalbumin alone. The number of eosinophils was determined in photographs taken of 10 random fields
of 10 different sections (Luna’s staining; see Figure S8B). (C) Effects of DS-70 eye drops on conjunctival eosinophil peroxidase levels 24 h after top-
ical challenge with ovalbumin. Data refer to the mean ± SD (five animals per group were included, and both eyes were evaluated; n = 10).
*P < 0.05, significantly different from saline + vehicle; #P < 0.05, significantly different from vehicle + OVA.
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Figure 6
Topical treatment with DS-70 in guinea pigs sensitized and challenged with ovalbumin reduces conjunctival levels of α4 integrin. (A) Photomicro-
graphs of the conjunctiva 24 h after topical challenge with ovalbumin and pretreatment with DS-70 (0.01, 0.05 and 0.1%). Black arrows in panel
A indicate hot spots of expression. (B) IHC score was assigned as reported in the Methods. Guinea pigs sensitized with saline and treated with the
vehicle used to dissolve DS-70 (saline + vehicle) showed basal levels of expression, as animals sensitized with saline and treated with DS-70 alone
(saline + DS-70 0.1%). In guinea pigs sensitized and challenged with ovalbumin and treated with the vehicle used to dissolve DS-70
(vehicle + OVA), IHC score is markedly increased, and DS-70 at the concentration 0.1% maximized the reduction that can be seen already
observed at 0.05%. Data are presented as the mean ± SD (five animals per group were included, and both eyes were evaluated; n = 10).
Black bars = 50 μm. *P < 0.05, significantly different from saline + vehicle; #P < 0.05, significantly different from vehicle + OVA.
S D Dattoli et al.
3904 British Journal of Pharmacology (2018) 175 3891–3910
eosinophilic leukaemia cell line, and HMC 1.1 cells, a human
mast cell line, all of which express integrin α4β1, to VCAM-1
and FN. Although DS-70 is eightfold less potent in preventing
the adhesion of RPMI 8866 cells that express α4β7 (Erle et al.,
1994) to MAdCAM-1 than cells that express α4β1 integrin,
DS-70 still prevents adhesion in the nanomolar range. Thus,
this novel compound may be considered a dual antagonist
of α4β1/α4β7 integrins. We further characterized DS-70 as an
effective antagonist of α4 integrin by showing that it antago-
nized VCAM-1-mediated phosphorylation of ERK 1/2 in
Jurkat E6.1 cells and VCAM-1-mediated degranulation of
HMC 1.1 mast cells and EoL-1 cells.
Consistent with other studies (Karanam et al., 2007), the
reference α4β1 integrin antagonist BIO1211 is metabolically
unstable when added to mouse serum in vitro (t1/2 = 2.1 h),
whereas only 21% of DS-70 was degraded under the same ex-
perimental conditions. These data further confirm the poten-
tial for DS-70 to be developed as drug for administration
in vivo. Following administration of DS-70 in the guinea pig
conjunctival fornix, it was detected in the conjunctiva.
Higher levels were measured 1 h later, but it was still present
6 h after treatment. These data provide more evidence for
the antiallergic effects that this agent promotes at conjuncti-
val level.
Figure 7
DS-70 eye drops (0.1% suspension) induced a significant down-regulation of IL-8, IL-1β, CCL5 and CCL11 transcripts in conjunctiva. Relative fold
changes in mRNA levels were calculated using the ΔΔCt method as described in the Methods. Ovalbumin challenged animals (vehicle + OVA) be-
have as positive control; DS-70 0.05% and DS-70 0.1% reduce this increase. Values are the mean ± SD (five animals per group were included, and
both eyes were evaluated; n = 10). *P < 0.05, significantly different from saline + vehicle; #P < 0.05, significantly different from vehicle + OVA.
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Using the mAb PE conjugated HUTS-21 that recognizes
a ligand-induced binding site epitope of β1 integrin
expressed with the α4 subunit (Luque et al., 1996), DS-70
concentration-dependently reduced the exposure of HUTS-
21 epitope, as measured by mAb binding in the presence
of the endogenous α4β1 agonist VCAM-1. Finally, in a
model of allergic conjunctivitis, DS-70 eye drops
dose-dependently antagonized the clinical symptoms of
conjunctival allergy and the conjunctival expression of α4
integrin by reducing infiltration of leukocytes, such as
eosinophils expressing this integrin in the conjunctiva, in-
cluding mast cells.
The α4β1 integrin/VCAM-1 pathway seems to be crucial
for the firm adhesion and transmigration of mast cells
(Parmley et al., 2007) and eosinophils (Nagata et al., 1998)
into the conjunctiva through vascular endothelial cells. The
inhibition of conjunctival eosinophil infiltration by an
integrinmAb has been reported in a guinea pigmodel of aller-
gic conjunctivitis (Ebihara et al., 1999). Furthermore, treat-
ment with anti-α4 integrin and anti-VCAM-1 antibodies
significantly suppressed the conjunctival eosinophil infiltra-
tion induced in mice following active immunization with
ragweed or adoptive transfer of ragweed-primed splenocytes
(Fukushima et al., 2006). As shown by Higashimoto et al.
(1999), the adhesion of eosinophils to FN is mediated by
α4β1 integrin, potentially contributing to the increased cell
adhesion to the extracellular matrix and conjunctival eosino-
phil accumulation.
Figure 8
DS-70 reduces CCL5 and CCL11 conjunctival expression. Conjunctival sections were examined by IHC for the expression of chemokines and the
IHC scores calculated. (A–C) Representative photographs stained with specific primary antibodies are shown. (B–D) IHC scores assigned. Tissue
sections from guinea pigs treated with saline (saline + vehicle) and DS-70 alone (saline + DS-70 0.1%) were used as a negative control. Scale
bar, 50 μm. Data are presented as mean ± SD (fie animals per group were included, and both eyes were evaluated; n = 10). *P< 0.05, significantly
different from saline + vehicle; #P < 0.05, significantly different from vehicle + OVA.
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These in vitro data may help to explain the reduction in
the expression of α4 integrin observed in the conjunctiva of
ovalbumin-sensitized guinea pigs treated with DS-70. In fact,
this effect might be a consequence of the DS-70-mediated re-
duction in the recruitment and migration of mast cells and
eosinophils to the site of allergic inflammation, rather than
of the down-regulation of α4β1 induced by DS-70. This hy-
pothesis is further supported by the findings that integrins in-
crease their affinity or avidity for endothelial-expressed
adhesion molecules upon exposure to chemokines and un-
dergo conformational changes upon ligand binding in addi-
tion to changes in their expression on the leukocyte surface
(Hyduk and Cybulsky, 2009).
We ascertained the positive effect of DS-70 eye drops on
inflammatory changes induced by allergen-specific conjunc-
tival challenge. This novel molecule, topically administered
prior to ovalbumin challenge, effectively and dose-
dependently reduced the conjunctival levels of the cytokines
IL-1β and IL-8 and of the chemokines CCL5 and CCL11 at
both mRNA and protein levels. Histamine and eicosanoids
are responsible for the typical early phase response (Katelaris,
2003). However, mast cells also contribute to the synthesis
and release of cytokines, chemokines and growth factors, trig-
gering a cascade of inflammatory events on the surface of ep-
ithelial and endothelial cells that leads to the late phase
reaction, along with the recruitment of eosinophils and neu-
trophils (Abelson et al., 2015). These latter cytokines partici-
pate in the production of chemokines, including CCL5 and
CCL11, from conjunctival cells. The chemokine gradient reg-
ulates the trafficking of neutrophils, eosinophils and lympho-
cytes to the conjunctiva occurring during the late phase.
CCL5 and CCL11 are included among major eosinophil
chemoattractants. Furthermore, they are produced by eosino-
phils and are released during allergic responses. Mast cells ex-
press receptors for CCL5 and CCL11 and other chemokines
that induce mast cell activation contributing to ongoing cel-
lular infiltration and conjunctival hyperresponsiveness of
the late phase (Komi et al., 2018). Inflammatory cytokines
may also enhance the expression of E-selectin, ICAM-1 and
VCAM-1 on vascular endothelial cells and initiate the rolling
and adhesion of immune cells (Bacon et al., 1998).
By reducingmast cell degranulation, DS-70 eye drops may
decrease the early phase response in ovalbumin-challenged
guinea pigs and contribute to the conjunctival eosinophil in-
filtration in the late phase response. Consequently, conjunc-
tival levels of cytokine and chemokine mRNAs are decreased
(Pacharn and Vichyanond, 2013). These effects are further
supported by α4 integrin localized on conjunctival mast cells
and eosinophils. Conjunctival epithelial cells do not express
α4β1 integrin (Fujihara et al., 1997), and its expression in the
conjunctiva may be derived from infiltrated inflammatory
cells and promoted by different mechanisms.
According to serum stability studies and detection of top-
ically applied DS-70 in the conjunctiva, it may be absorbed by
conjunctival blood vessels and may persist at an adequate
conjunctival concentration for up to 6–8 h, a sufficient pe-
riod to interfere with mast cell activation and eosinophil mi-
gration to the ocular surface. We propose DS-70 as a novel α4
integrin antagonist capable of relieving symptoms of allergic
conjunctivitis in an appropriate animal model, and some of
the targets of this drug include the conjunctival infiltration
of mast cells and eosinophils and the reduction of α4 integrin
expression.
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Figure S1 Relevant steps of the synthesis designed for DS-70
(A) and DS-23 (B) compounds, as described in the Methods.
Figure S2 [125I]-FN binds to the complex between α4β1
integrin and the antibody anti-α4 integrin in the presence of
scintillation beads coated with an anti-rabbit IgG antibody
(the procedure is described in the Methods). (A) Representa-
tive autoradiogram of a western blot experiment, evaluating,
separately, α4 and β1 integrin subunits in cell lysate fractions
(1–4) of Jurkat E6.1 cells, expressing α4β1 integrin. Fractions
1–4 were used in the SPA assays. (B) Saturation SPA binding
of [125I]-FN to α4β1 integrin extracted and purified from Jurkat
E6.1 cells and incubated with antibody anti-α4 integrin, scin-
tillation beads coated with the anti-rabbit IgG antibody and
the radioligand. Non-specific binding was determined in the
presence of increasing concentrations of [125I]-FN
(1–25 nM) and of 100 nM BIO1211. Saturation specific bind-
ing was determined by subtracting the non-specific binding
from total binding counts. [125I]-FN bound was expressed as
counts per minute (cpm). Data are presented as mean ± SEM
of five experiments in triplicate.
Figure S3 Flow cytometry plots (number of cells count vs.
green fluorescence) showing relative surface expression of
integrin α4 (filled peak) on all cell lines employed in in vitro
experiments 4 compared with isotype control mAb (negative
controls, empty peak). The fluorescence shifts reported for
Jurkat E6.1, EoL-1 and HMC 1.1 cells confirmed that these
cell lines strongly express α4 integrin on their surface, while
all other cell lines do not express α4 integrin. A representative
result of five independent experiments carried out in tripli-
cate (n = 5) is shown.
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Figure S4 Degradation of BIO1211 and DS-70 in mouse se-
rum. Samples were removed from the incubation solution at
0, 0.15, 0.5, 1.0, 2.0, 4.0, 6.0 and 8.0 h and peptide stability
was determined using an RP-HPLC ESI-MS analysis (described
in the Methods). Values are presented as mean ± SD (n = 5).
Figure S5 Effects of DS-70 on ERK 1/2 phosphorylation me-
diated by VCAM-1 in HMC1.1 (A, B) and EoL-1 cells (C, D).
(A, C) Representative Western blots confirmed that VCAM-1
is able to induce ERK 1/2 phosphorylation in both cell lines
and DS-70 maintains its inhibitory effect on this signal trans-
duction pathway. (B, D) The results of semi-quantitative den-
sitometry analysis of the bands from five independent
experiments are shown (mean ± SD); the amount of pERK
1/2 is normalized to that of total ERK 1/2. *P < 0.05 vs. vehi-
cle; #P < 0.05 vs. VCAM-1.
Figure S6 DS-70 does not induce apoptosis in Jurkat E6.1,
EoL-1 and HMC1.1 cell lines. Density plots showing the
percentage distribution of Jurkat E6.1, HMC 1.1 and EoL-1
control and vehicle or DS-70 (104 M; 6 h) treated cells. Apo-
ptotic and necrotic cells were quantified by flow cytometry as
described in Methods. Non-apoptotic cells (Annexin V and 7-
AAD negative) represent 90–95% of the total cell population
after treatment. Quadrants: (top left) damaged cells, (top
right) late apoptotic/secondary necrotic cells, (lower left) live
cells, (lower right) early apoptotic cells. These figures are from
a representative experiment carried out at least five times in
triplicate.
Figure S7 Effects of dexamethasone (Dex) on conjunctival
symptoms induced by ovalbumin (OVA) in guinea pigs.
Guinea pigs sensitized and challenged with ovalbumin and
treated with the vehicle used to dissolve DS-70 (vehicle
+OVA) were responsive to the treatment with the consequent
increase in clinical score index. Administration of Dex signif-
icantly counteracts pathological signs and improves eye ap-
pearance. In control guinea pigs sensitized with saline and
treated with the vehicle (saline+vehicle) or Dex (saline +
Dex 0.1%) no signs of allergic conjunctivitis were observed.
Data are presented as scatter plot and refer to the mean ± SD
(5 animals per group were included and both eyes were evalu-
ated; n = 10). *P < 0.05 vs. saline + vehicle; #P < 0.05 vs. vehi-
cle + OVA.
Figure S8 DS-70 prevents, in a dose-dependent manner,
conjunctival infiltration and degranulation of mast cells
and eosinophils. (A) Histologic analysis of OVA-mediated
conjunctival mast cell degranulation. Photomicrographs of
tarsal conjunctiva stained with May-Grünwald-Giemsa. Both
metachromatic (m) and degranulated (d) mast cells are
shown. Black bar = 25 μm. (B) Substantial eosinophil infiltra-
tion (Luna’s staining) is observed in OVA-treated guinea pigs
(vehicle+OVA) in comparison to animals sensitized with
saline and treated with the vehicle used to dissolve DS-70
(saline+vehicle) and to animals sensitized with saline and
treated with DS-70 alone (saline+DS-70 0.1%) (5 animals per
group were included and both eyes were evaluated; n = 10).
Scale bar = 100 μm.
Figure S9 Co-localization of mast cell tryptase or MBP
(major basic protein), markers for mast cells and eosinophils
respectively, with α4 integrin in conjunctival sections of
guinea pigs sensitized and challenged with ovalbumin and
treated with DS-70. (A) Mast cell tryptase and α4 integrin co-
localize on mast cells in conjunctival sections of guinea pig.
Double immunofluorescence staining images for tryptase
(green) and α4 integrin (red) are shown. (B) MBP and α4
integrin colocalize on eosinophils in conjunctival sections
of guinea pig. Double immunofluorescence staining images
for MBP (green) and α4 integrin (red) are shown (5 animals
per group were included and both eyes were evaluated;
n = 10). Scale bar = 50 μm.
Table S1 Primers employed in real time PCR experiments.
Table S2 Cell lines employed in the study; for each cell lines
culture medium, integrin mainly expressed and some refer-
ences are indicated.
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